We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office.
Shah
Gaurav Y
GY
Ambatipudi
Srinivas
S
Fernandes
Merle
M
Lakshmipathy
Meena
M
Varma
P V K S
PV
Sachdeva
Virender
V
Pathengay
Avinash
A
D000556:Ambulatory Surgical Procedures; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D009877:Endophthalmitis / Q000453:epidemiology / Q000209:etiology*; D015818:Eye Infections, Bacterial / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D013203:Staphylococcal Infections / Q000453:epidemiology / Q000209:etiology; D013212:Staphylococcus epidermidis / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000453:epidemiology / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D034363:Viridans Streptococci / Q000302:isolation & purification; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab